41 completed, 13 terminated, 9 recruiting, 7 withdrawn. 80 Phase 1, 32 Phase 2.
Follow Rapamycin: new trials by email Literature Review of Rapamycin trials Research Report on Rapamycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH) | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 15 | 2027-01-01 | 2026-06-25 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Familial Platelet Disorder With Associated Myeloid Malignancy | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 6 | 2026-10-05 | 2026-10-13 |
| Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma Sirolimus, Teclistamab, Talquetamb - Multiple Myeloma | Phase 1 | Recruiting | Christopher Strouse | 10 | 2026-06-01 | 2026-06-04 |
| A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation lamivudine, rapamycin, Exercise Regimen - Smokers, Former Smokers | Phase 1 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 20 | 2025-08-12 | 2026-08-27 |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-07-01 | 2026-10-30 |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies UB-VV400, Rapamycin - Large B-cell Lymphoma | Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | 70 | 2025-04-11 | 2025-09-18 |
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies UB-VV111, rapamycin - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) | Phase 1 | Recruiting | Umoja Biopharma | 106 | 2025-03-10 | 2026-10-15 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Rapalog Pharmacology (RAP PAC) Study Sirolimus, Everolimus - Aging | Phase 1 | Recruiting | University of Wisconsin, Madison | 72 | 2024-05-15 | 2026-05-28 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography Sirolimus - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Karolinska Institutet | 14 | 2023-09-01 | 2025-07-03 |
| Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome low-dose interleukin-2, rapamycin - Sjögren's Syndrome | Phase 1 / Phase 2 | Completed | Peking University People's Hospital | 30 | 2022-12-05 | 2024-07-09 |
| TMLI and Alemtuzumab for Treatment of Sickle Cell Disease Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy - Sickle Cell Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 20 | 2022-07-13 | 2026-07-30 |
| Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults Rapamune - Heart Failure | Phase 1 | Completed | Mayo Clinic | 24 | 2022-05-24 | 2023-09-28 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2021-04-30 | 2026-07-13 |
| Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS Rapamycin, Placebo - Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure | Phase 1 / Phase 2 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2021-04-01 | 2021-06-01 | |
| Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer Durvalumab, Sirolimus - Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 1 | Terminated | Emory University | 3 | 2021-01-22 | 2024-08-22 |
Showing 20 of 80. Sign in to see all of them.
Multiple Myeloma (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Anemia, Sickle Cell (4) · Carcinoma, Hepatocellular (4) · Carcinoma, Non-Small-Cell Lung (4) · Hematologic Neoplasms (4) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Primary Myelofibrosis (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, Non-Hodgkin (3) · Melanoma (3) · Myelodysplastic Syndromes (3) · Neoplasm Metastasis (3)
City of Hope Medical Center (7) · Mayo Clinic (7) · University of Chicago (4) · National Eye Institute (NEI) (3) · OHSU Knight Cancer Institute (3) · Roswell Park Cancer Institute (3) · Yale University (3) · Children's Hospital of Philadelphia (2) · Columbia University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Stanford University (2) · University of Washington (2) · AIDS Malignancy Consortium (1) · Abramson Cancer Center at Penn Medicine (1) · Cedars-Sinai Medical Center (1)
United States (68) · China (5) · Sweden (2) · Australia (1) · Germany (1) · Italy (1) · Netherlands (1) · Russia (1) · Singapore (1) · Spain (1)
Kunle Odunsi (3) · Ezra Cohen, MD (2) · Haris Ali (2) · Mandeep Singh, MD (2) · Robert Montgomery (2) · Aaron R Weiss, DO (1) · Adam Konopka, PhD (1) · AeRang Kim, MD, PhD (1) · Aldo T Iacono, MD (1) · Anna Pawlowska (1) · Blake Rasmussen, PhD (1) · Brando Triplett, MD (1) · Brigitte Widemann, MD (1) · Carla Greenbaum, MD (1) · Chao Huang, MD (1)
PMID 40132910, PMID 16030064, PMID 16614412, PMID 16873412, PMID 16896165, PMID 17351147, PMID 17478528, PMID 17569770, PMID 17885021, PMID 18056791, PMID 18215105, PMID 18236467, PMID 18317375, PMID 18323467, PMID 18342407, PMID 18347658, PMID 18403916, PMID 18535123, PMID 18713956, PMID 18787087, PMID 18827171, PMID 18845784, PMID 19057193, PMID 19150856, PMID 19188252, PMID 19208097, PMID 19828686, PMID 19950289, PMID 20070283, PMID 20150565, PMID 20304764, PMID 20519362, PMID 20844186, PMID 20876843, PMID 21076294, PMID 21430254, PMID 21527663, PMID 21529326, PMID 21606874, PMID 21798089, PMID 22338078, PMID 22362401, PMID 22644638, PMID 22721971, PMID 22889597, PMID 22959478, PMID 23055316, PMID 23089333, PMID 23265712, PMID 23343671
P30CA015083 (2), P30CA015704 (2), P30CA016056 (2), P30CA033572 (2), P30CA069533 (2), R01CA158318 (2), 2023 (1), P01HL122173 (1), P30CA138292 (1), P50CA097186 (1), P50CA217691 (1), R01AR049877 (1), U01AG081482 (1), U01CA070019 (1), UM1CA186691 (1)